Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee

WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
October 25, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference

WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
June 15, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22nd

WALTHAM, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients...
April 13, 2016 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
October 28, 2015 17:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics to Present at the BIO-Europe 2015 Conference November 3

WALTHAM, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
October 12, 2015 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015

WALTHAM, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
September 01, 2015 07:30 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory Affairs

WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
August 12, 2015 07:30 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Initiates Second Phase 3 Clinical Study of Investigational Drug Vonapanitase

WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
June 02, 2015 08:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing

WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
May 22, 2015 07:00 ET | Source: Proteon Therapeutics, Inc.

Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual Congress

WALTHAM, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...

Next Page keyboard_arrow_right